Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables (2016 - 2026)

Heron Therapeutics filings provide 15 years of Change in Account Payables readings, the most recent being -$24000.0 for Q1 2026.

  • On a quarterly basis, Change in Account Payables fell 103.85% to -$24000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.4 million, a 129.25% decrease, with the full-year FY2025 number at -$2.7 million, down 132.06% from a year prior.
  • Change in Account Payables hit -$24000.0 in Q1 2026 for Heron Therapeutics, up from -$3.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.4 million in Q2 2024 to a low of -$7.3 million in Q3 2022.
  • Median Change in Account Payables over the past 5 years was -$24000.0 (2026), compared with a mean of $303941.2.
  • The widest YoY moves for Change in Account Payables: up 545.4% in 2024, down 386.07% in 2024.
  • Heron Therapeutics' Change in Account Payables stood at -$3.3 million in 2022, then skyrocketed by 141.54% to $1.4 million in 2023, then increased by 10.22% to $1.5 million in 2024, then tumbled by 298.75% to -$3.0 million in 2025, then soared by 99.21% to -$24000.0 in 2026.
  • The last three reported values for Change in Account Payables were -$24000.0 (Q1 2026), -$3.0 million (Q4 2025), and -$20000.0 (Q3 2025) per Business Quant data.